文献速递白血病

强化治疗儿童B淋巴细胞白血病伴IKZF1缺失可降低复发并改善总生存:马来西亚-新加坡ALL 2010研究结果

Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
PubMed 文献 · J Clin Oncol · 2018-07-25

该研究比较MS2003与MS2010两个队列中伴IKZF1缺失的儿童B-ALL患者,MS2010将IKZF1缺失风险等级上调并强化治疗。结果显示MS2010中IKZF1缺失患者5年累积复发率降至13.5%,5年总生存率从69.6%提高至91.6%。

要点

  • MS2010将IKZF1缺失患者风险等级上调至下一最高等级并强化治疗。
  • 伴IKZF1缺失患者5年累积复发率从MS2003的30.4%降至MS2010的13.5%。
  • 伴IKZF1缺失患者5年总生存率从MS2003的69.6%提高至MS2010的91.6%。

核心结论

  • 对伴IKZF1缺失的儿童B-ALL强化治疗显著降低复发风险并改善总生存。
  • 将IKZF1缺失筛查纳入风险分层可显著改善当代ALL治疗结局。

研究设计与样本

  • MS2010为前瞻性研究,将IKZF1缺失患者风险等级上调至下一最高等级,并在所有BCR-ABL1融合患者中加入伊马替尼治疗。
  • 共筛查823例B-ALL患者,其中MS2003队列507例、MS2010队列316例,采用多重连接依赖探针扩增法检测IKZF1缺失。
  • 比较两个研究中IKZF1缺失对5年累积复发率的影响。

主要发现

  • 两队列患者特征相似,IKZF1缺失频率分别为MS2003组59/410(14.4%)与MS2010组50/275(18.2%)(P=0.2)。
  • 在未将IKZF1缺失用于风险分层的MS2003中,IKZF1缺失患者5年累积复发率显著更高(30.4% vs 8.1%;P=8.7×10^-7),尤其在高危特征缺失的中危组(25.0% vs 7.5%;P=0.01)。
  • 在BCR-ABL1阴性患者中,MS2003的IKZF1缺失患者5年累积复发率更高(20.5% vs 8.0%;P=0.01)。
  • MS2010中IKZF1缺失患者5年累积复发率显著降至13.5%(P=0.05),BCR-ABL1阴性患者中不再有显著差异(11.4% vs 4.4%;P=0.09)。
  • IKZF1缺失患者5年总生存率从MS2003的69.6%提高至MS2010的91.6%(P=0.007)。

临床怎么用

  • 作者结论认为,对伴IKZF1缺失的儿童B-ALL强化治疗可显著降低复发风险并改善总生存。
  • 作者结论认为,将IKZF1缺失筛查纳入风险分层可显著改善当代ALL治疗结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Although IKZF1 deletion ( IKZF1del) confers a higher risk of relapse in childhood B-cell acute lymphoblastic leukemia (B-ALL), it is uncertain whether treatment intensification will reverse this risk and improve outcomes. The Malaysia-Singapore ALL 2010 study (MS2010) prospectively upgraded the risk assignment of patients with IKZF1del to the next highest level and added imatinib to the treatment of all patients with BCR- ABL1 fusion. Patients and Methods In total, 823 patients with B-ALL treated in the Malyasia-Singapore ALL 2003 study (MS2003; n = 507) and MS2010 (n = 316) were screened for IKZF1del using the multiplex ligation-dependent probe amplification assay. The impact of IKZF1del on the 5-year cumulative incidence of relapse (CIR) was compared between the two studies. Results Patient characteristics were similar in both cohorts, including IKZF1del frequencies (59 of 410 [14.4%] v 50 of 275 [18.2%]; P = .2). In MS2003, where IKZF1del was not used in risk assignment, IKZF1del conferred a significantly higher 5-year CIR (30.4% v 8.1%; P = 8.7 × 10-7), particularly in the intermediate-risk group who lacked high-risk features (25.0% v 7.5%; P = .01). For patients with BCR-ABL1-negative disease, IKZF1del conferred a higher 5-year CIR (20.5% v 8.0%; P = .01). In MS2010, the 5-year CIR of patients with IKZF1del significantly decreased to 13.5% ( P = .05) and no longer showed a significant difference in patients with BCR-ABL1-negative disease (11.4% v 4.4%; P = .09). The 5-year overall survival for patients with IKZF1del improved from 69.6% in MS2003 to 91.6% in MS2010 ( P = .007). Conclusion Intensifying therapy for childhood B-ALL with IKZF1del significantly reduced the risk of relapse and improved overall survival. Incorporating IKZF1del screening significantly improved treatment outcomes in contemporary ALL therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yeoh AEJ, Lu Y, Chin WHN, et al. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study. J Clin Oncol. 2018. PMID: 30044693. doi:10.1200/JCO.2018.78.3050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。